15 completed, 5 terminated, 3 withdrawn, 2 recruiting. 27 Phase 2, 5 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 27 | Completed 15, Terminated 5, Withdrawn 3, Recruiting 2, Unknown 2 |
| Phase 3 | 5 | Completed 2, Terminated 2, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
Follow Dyskinesia, Drug-Induced: new trials by email Literature Review of Dyskinesia, Drug-Induced trials Research Report on Dyskinesia, Drug-Induced
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia NBI-1065890, Placebo - Tardive Dyskinesia | Phase 2 | Recruiting | Neurocrine Biosciences | 100 | 2026-02-06 | 2026-06-23 |
| Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia LPM3770164 sustained release tablet 5 mg, LPM3770164 sustained release tablet 10 mg, LPM3770164 sustained release tablet 20 mg - Tardive Dyskinesia (TD) | Phase 1 / Phase 2 | Recruiting | Luye Pharma Group Ltd. | 120 | 2025-01-14 | 2025-01-22 |
| AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia AV-101, Placebo - Parkinson Disease, Dyskinesia, Medication-Induced | Phase 2 | Unknown | VistaGen Therapeutics, Inc. | 20 | 2022-08-01 | 2021-05-26 |
| Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia NLX-112, Placebo - Medication-Induced Dyskinesia | Phase 2 | Completed | Neurolixis SAS | 27 | 2021-11-09 | 2024-04-23 |
| Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia CPL500036 - low dose, CPL500036 - high dose, Placebo - Parkinson Disease, Dyskinesia, Medication-Induced | Phase 2 | Completed | Celon Pharma SA | 105 | 2021-11-02 | 2025-03-04 |
| Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy Dipraglurant - Parkinson Disease, Dyskinesia, Drug-Induced | Phase 2 / Phase 3 | Terminated | Addex Pharma S.A. | 17 | 2021-10-25 | 2025-08-06 |
| Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy Dipraglurant, Placebo - Parkinson Disease, Dyskinesia, Drug-Induced | Phase 2 / Phase 3 | Terminated | Addex Pharma S.A. | 25 | 2021-08-06 | 2025-08-06 |
| Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia Propranolol Hydrochloride, Placebo Oral Tablet - Tardive Dyskinesia | Phase 2 / Phase 3 | Withdrawn | Emory University | 2017-09-18 | 2019-02-26 | |
| Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia MT-5199, Placebo - Tardive Dyskinesia | Phase 2 / Phase 3 | Completed | Tanabe Pharma Corporation | 256 | 2017-06-21 | 2026-01-07 |
| Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS) tSMS, sham - Dyskinesia, Medication-Induced, Parkinson's Disease | Phase 2 | Completed | Fundación de investigación HM | 50 | 2015-10-01 | 2018-10-11 |
| Heart Rate Variability in Response to Metformin Challenge Metformin - Fibromyalgia, Mitochondrial Diseases | Phase 2 | Completed | Woodinville Psychiatric Associates | 61 | 2015-07-01 | 2018-01-03 |
| Aim to Reduce Movements in Tardive Dyskinesia SD-809, Placebo - Tardive Dyskinesia | Phase 2 / Phase 3 | Completed | Auspex Pharmaceuticals, Inc. | 117 | 2014-06-01 | 2021-11-09 |
| A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia SNC-102, Placebo - Drug-induced Tardive Dyskinesia | Phase 2 | Withdrawn | Synchroneuron Inc. | 2014-02-01 | 2021-04-13 | |
| Dysport for the Treatment of OMD Low Dose - AbobotulinumtoxinA - Oral Dystonia, Tardive Dystonia | Phase 1 / Phase 2 | Completed | Emory University | 18 | 2013-08-01 | 2017-11-17 |
| Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease Topiramate, Placebo, Amantadine - Idiopathic Parkinson's Disease, Drug Induced Dyskinesia | Phase 2 | Terminated | Rush University Medical Center | 42 | 2013-03-01 | 2019-04-16 |
| NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia NBI-98854, Placebo - Tardive Dyskinesia | Phase 2 | Completed | Neurocrine Biosciences | 102 | 2012-12-01 | 2017-08-10 |
| NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) NBI-98854, Placebo - Tardive Dyskinesia | Phase 2 | Completed | Neurocrine Biosciences | 109 | 2012-09-01 | 2017-11-08 |
| NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder NBI-98854, Placebo - Tardive Dyskinesia | Phase 2 | Completed | Neurocrine Biosciences | 37 | 2011-08-01 | 2017-08-10 |
| Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia NBI-98854 - Tardive Dyskinesia | Phase 2 | Completed | Neurocrine Biosciences | 10 | 2011-01-01 | 2011-04-20 |
| Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias AFQ056 - Parkinson Disease, Dyskinesia, Drug-Induced | Phase 2 | Completed | Novartis Pharmaceuticals | 66 | 2010-10-01 | 2020-12-23 |
Showing 20 of 27. Sign in to see all of them.
Tardive Dyskinesia (17) · Parkinson Disease (8) · Dyskinesias (6) · Schizophrenia (4) · Movement Disorders (3) · Psychotic Disorders (2) · Akathisia, Drug-Induced (1) · Central Nervous System Diseases (1) · Delusions (1) · Dementia (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Dystonia (1) · Fibromyalgia (1)
Pathological Conditions, Signs and Symptoms (27) · Central Nervous System Diseases (26) · Nervous System Diseases (26) · Neurologic Manifestations (26) · Signs and Symptoms (26) · Movement Disorders (24) · Dyskinesias (21) · Chemically-Induced Disorders (11) · Neurotoxicity Syndromes (11) · Poisoning (11) · Basal Ganglia Diseases (10) · Brain Diseases (10) · Drug-Related Side Effects and Adverse Reactions (10) · Neurodegenerative Diseases (8)
valbenazine (4) · 6-fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine (2) · 2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine (1) · Acamprosate (1) · Amantadine (1) · Asian ginseng (1) · Deep Brain Stimulation (1) · Fish Oils (1) · Levetiracetam (1) · Metformin (1) · PHA-568487E (1) · Propranolol (1) · Pyridoxal Phosphate (1) · Sugars (1) · Topiramate (1)
Neurocrine Biosciences (5) · Addex Pharma S.A. (2) · Emory University (2) · Auspex Pharmaceuticals, Inc. (1) · Celon Pharma SA (1) · Charite University, Berlin, Germany (1) · Fundación de investigación HM (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Luye Pharma Group Ltd. (1) · Medicure (1) · Merck Sharp & Dohme LLC (1) · Neurolixis SAS (1) · Novartis Pharmaceuticals (1) · Rush University Medical Center (1) · Synchroneuron Inc. (1)
United States (12) · Canada (5) · Germany (3) · Poland (2) · Puerto Rico (2) · Australia (1) · Belgium (1) · Bulgaria (1) · China (1) · Czechia (1) · France (1) · India (1) · Italy (1) · Japan (1) · Slovakia (1)
Chris O'Brien, MD (2) · Adrian Newman-Tancredi, PhD (1) · Andreas R Kupsch, MD (1) · Christopher G Goetz, MD (1) · Christopher O'Brien, MD (1) · Gary J. Remington, MD, PhD (1) · Guglielmo Foffani, PhD (1) · Jaime Hatcher-Martin, MD, PhD (1) · Jon E Berner, MD PhD (1) · Per Svenningsson, Professor (1) · Pierre J. Blanchet, MD, PhD (1)
PMID 31617235, PMID 28404690, PMID 30249417, PMID 36114799, PMID 38421921, PMID 38557959, PMID 39186921
2005 (1), 2025 (1)